Baidu
map

EASL 2014:肝移植供体因素应纳入移植术后HCC复发因素中

2014-04-14 佚名 dxy

肝细胞癌(HCC)在移植术后复发率约为10%-15%。迄今为止的研究多关注于移植术接受者本身的特征因素对术后复发的影响,而较少关注于移植供体者的特点对接受者术后复发的影响。 瑞士日内瓦大学医院移植外科Orci等进行了一项研究,旨在探讨供体特征和供肝质量对接受者移植术后复发的风险影响。 该研究的对象为2004年至2011年间接受肝移植术的患者,进行多因素Cox比例风险回归分析。结果显示,9724例接

肝细胞癌(HCC)在移植术后复发率约为10%-15%。迄今为止的研究多关注于移植术接受者本身的特征因素对术后复发的影响,而较少关注于移植供体者的特点对接受者术后复发的影响。

瑞士日内瓦大学医院移植外科Orci等进行了一项研究,旨在探讨供体特征和供肝质量对接受者移植术后复发的风险影响。

该研究的对象为2004年至2011年间接受肝移植术的患者,进行多因素Cox比例风险回归分析。结果显示,9724例接受肝移植术患者中,5年累计复发率为7.8%。

调整混杂因素后,如下几个供体因素具有较高的受者术后复发风险:捐赠者年龄超过60岁、供者有糖尿病、供者肥胖II级等。

该研究表明,对于接受肝移植手术的患者评估术后HCC复发风险,除了考虑肿瘤本身的特点外,还要考虑将供肝者的高龄、BMI指数、糖尿病等因素纳入复发风险评估。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1631836, encodeId=67491631836b7, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Wed Jun 04 14:34:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998870, encodeId=22bb19988e065, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 04 04:34:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259472, encodeId=c00812594e2ee, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412503, encodeId=56cb1412503c2, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519165, encodeId=3c0b151916595, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
    2014-06-04 feather85
  2. [GetPortalCommentsPageByObjectIdResponse(id=1631836, encodeId=67491631836b7, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Wed Jun 04 14:34:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998870, encodeId=22bb19988e065, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 04 04:34:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259472, encodeId=c00812594e2ee, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412503, encodeId=56cb1412503c2, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519165, encodeId=3c0b151916595, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
    2014-07-04 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1631836, encodeId=67491631836b7, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Wed Jun 04 14:34:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998870, encodeId=22bb19988e065, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 04 04:34:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259472, encodeId=c00812594e2ee, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412503, encodeId=56cb1412503c2, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519165, encodeId=3c0b151916595, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
    2014-04-16 智智灵药
  4. [GetPortalCommentsPageByObjectIdResponse(id=1631836, encodeId=67491631836b7, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Wed Jun 04 14:34:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998870, encodeId=22bb19988e065, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 04 04:34:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259472, encodeId=c00812594e2ee, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412503, encodeId=56cb1412503c2, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519165, encodeId=3c0b151916595, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
    2014-04-16 kord1983
  5. [GetPortalCommentsPageByObjectIdResponse(id=1631836, encodeId=67491631836b7, content=<a href='/topic/show?id=bd782682e3a' target=_blank style='color:#2F92EE;'>#供体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26827, encryptionId=bd782682e3a, topicName=供体)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ed21829086, createdName=feather85, createdTime=Wed Jun 04 14:34:00 CST 2014, time=2014-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1998870, encodeId=22bb19988e065, content=<a href='/topic/show?id=8e2ee5200ee' target=_blank style='color:#2F92EE;'>#移植术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75200, encryptionId=8e2ee5200ee, topicName=移植术)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 04 04:34:00 CST 2014, time=2014-07-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1259472, encodeId=c00812594e2ee, content=<a href='/topic/show?id=2200854517' target=_blank style='color:#2F92EE;'>#HCC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8545, encryptionId=2200854517, topicName=HCC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1412503, encodeId=56cb1412503c2, content=<a href='/topic/show?id=ebcd6442dc' target=_blank style='color:#2F92EE;'>#EASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6442, encryptionId=ebcd6442dc, topicName=EASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0c52872504, createdName=kord1983, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1519165, encodeId=3c0b151916595, content=<a href='/topic/show?id=2082286e7b' target=_blank style='color:#2F92EE;'>#ASL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2867, encryptionId=2082286e7b, topicName=ASL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1a311248160, createdName=lq1771, createdTime=Wed Apr 16 04:34:00 CST 2014, time=2014-04-16, status=1, ipAttribution=)]
    2014-04-16 lq1771

相关资讯

中国成功实施新型晚期肝癌切除术

  7月18日,新型肝脏肿瘤切除手术在四川省人民医院成功实施。 沈依宣 摄   7月18日,四川省人民医院器官移植中心成功实施了一种全新的肝癌切除手术,目前患者病情稳定。这标志着我国晚期肝肿瘤的根治性手术取得新的进展。   据了解,这种手术于2012年在德国首创,正式名称为联合肝脏分割和门静脉结扎的分阶段肝切除术,简称ALPPS,是晚期肝肿瘤的根治性手术。   据院方介绍,49岁

陈佰义:感染科光靠吃“肝饭”是要挨饿的

传染病科更名为感染病科已经有一些年数了,但是感染病科以肝炎为中心,同时涉及了肝癌、肝硬化并发症、脂肪肝诊治;感染病科的医生对于抗菌药物仍然陌生;感染病学的年会被大量的肝病报道占据。感染病是否需要将肝病科分离出来,这是一个大胆的话题,值得讨论。 对此,中国医科大学第一医院感染病科陈佰义介绍说,该院立足临床需求将传染病科和感染病科独立设置,拥有传染病科的独立建筑,设有肝病门诊、肠道问诊(夏季

EASL 2014:延长PEG-IFNα-2a+替诺福韦疗程对丁肝预后无益

丁型肝炎是慢性病毒性肝炎中最严重的一种类型,聚乙二醇干扰素α治疗1.0-1.5年的有效率为25%-30%。HIDIT-2试验旨在探索使用PEG-IFNα-2a+替诺福韦或安慰剂治疗丁肝患者,延长疗程到96周对预后是否有益。4月10日的EASL2014会议上,德国汉诺威医学院Wedemeyer等对患者治疗结束后24周的疗效分析结果进行了报道。 研究共招募来自4个国家的120例HDV-RNA阳性患者,

FDA顾问小组全票拒绝批准肝转移性黑色素瘤药物设备Melblez Kit

美国食品药品管理局(FDA)的一个顾问小组认为,使用药物设备组合Melblez Kit直接将美法仑(左旋溶肉瘤素)输送到肝转移性葡萄膜恶性黑色素瘤患者的肝脏内,其风险超过任何可能的治疗收益,顾问小以16比0的投票结果拒绝批准该药物设备。在FDA的一次肿瘤药物顾问委员会上,几位专家小组成员表示,这种药物设备很有前途,但考虑到它明显的毒性以及对总生存期缺乏影响,这种药物设备仍需要进行试验研究。Melb

Mol Cell Bio:紧密连接蛋白促进乳腺癌肝转移

紧密连接蛋白与恶性肿瘤的发生和发展有着密切关系,Claudin蛋白是细胞间的紧密连接蛋白的主要结构之一。Claudin蛋白目前研究较多,其中与恶性肿瘤相关的Claudin蛋白主要有7种,不同的肿瘤组织表达的Claudin类蛋白种类、量是不同的,在研究恶性肿瘤诊断、治疗的新手段方面,Claudin蛋白有很大前景。 早期研究确定蛋白紧密连接-2(claudin-2)是乳腺癌肝转移的重要功能性调解因子

EASL 2014:大块肝坏死为慢加急性肝衰竭的重要病理指标

由于缺乏病理证据区分慢加急性肝衰竭(ACLF)和终末期肝硬化患者,常常认为ACLF这一定义是不准确的。上海交通大学医学院附属仁济医院李海等的一项前瞻性单中心研究发现,大块肝坏死(MHN)这一病理特征可作为区别ACLF患者和肝硬化急性失代偿期患者的重要指标。 该研究共纳入174例患者,这些患者均为慢乙肝感染导致肝硬化后接受了肝移植手术。按病理发现是否存在MHN分为两组。对患者肝功能和器官衰竭情况进行

Baidu
map
Baidu
map
Baidu
map